TRACON ($NASDAQ:TCON) Pharmaceuticals is a biopharmaceutical company focused on developing therapies for cancer and other unmet medical needs. Recently, the company has licensed its product development platform for an upfront payment of $3M. This platform focuses on the discovery and development of novel therapeutics for the treatment of cancer and other serious diseases. The platform includes multiple discovery tools and preclinical models that are used to identify and validate drug targets. It also includes a suite of proprietary technologies, including TRACON’s proprietary screening and profiling technology and a highly refined humanized mouse model. Utilizing these tools, TRACON is able to identify, develop, and advance new drug candidates into clinical trials with greater speed and efficiency than ever before.
This licensing agreement is the latest in a string of successes for TRACON. Just recently, the company announced they had secured an exclusive license to the small molecule inhibitor program of a major European research institute. This is expected to significantly accelerate the development of new cancer medicines for clinical testing. TRACON is committed to delivering innovative therapeutics to patients who are in desperate need of treatments for serious diseases such as cancer. This latest agreement ensures that the company will continue to bring cutting-edge treatments to market, while also providing value to its shareholders.
On Monday, TRACON Pharmaceuticals (TRACON) announced that it had entered into a licensing agreement with a top-tier biopharmaceutical company to develop and commercialize a new product development platform. Following the announcement, TRACON’s stock opened up at $0.2 and closed at $0.2, up 3.3% from the previous closing price of 0.2. This agreement highlights TRACON’s dedication to innovative drug development and its commitment to delivering high-quality, cost-effective treatments to patients. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Tracon Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tracon Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tracon Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Tracon Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale recently conducted an analysis of TRACON PHARMACEUTICALS‘s wellbeing. Based on our Star Chart assessment, TRACON PHARMACEUTICALS has a health score of 2/10, indicating that it is less likely to sustain future operations in times of crisis. Our analysis also classified them as a ‘cheetah’ type of company, which means they have achieved high revenue or earnings growth yet are considered less stable due to lower profitability. Given their strengths in growth and weaknesses in asset, dividend, and profitability, investors who prioritize rapid growth yet understand the associated risks may be interested in investing in TRACON PHARMACEUTICALS. As a company focused on growth, they may present a good opportunity for those risk-tolerant investors looking for a potential long-term return. More…
Star Chart Analysis
It has a range of competitors, such as Advaxis Inc, Xencor Inc, and Lumos Pharma Inc. All four companies are dedicated to delivering innovative treatments to improve the lives of patients living with cancer and other serious diseases.
Advaaxis Inc is a biotechnology company that develops cancer immunotherapies based on its proprietary platform technology. The company’s market cap as of 2023 is 8.82M, which suggests that it is a relatively small company. However, its Return on Equity of -183.87% suggests that the company is not performing well. This is likely due to the fact that the company is still in the early stages of developing its products and has yet to commercialize them. As such, it may take some time before Advaaxis can begin to realize its full potential.
Xencor Inc is a biopharmaceutical company based in California that specializes in developing monoclonal antibody-based therapeutics for treating cancer, asthma, and autoimmune diseases. As of 2023, the company has a market cap of 1.21 billion dollars and a Return on Equity (ROE) of -13.56%. A negative ROE indicates that the company has not yet been able to generate enough earnings to reflect the capital invested by shareholders. This is a signal for investors to be cautious about investing in the company.
Lumos Pharma Inc is a biotechnology company focused on discovering and developing innovative therapies for treating rare diseases. It has a market capitalization of 24.22 million U.S. dollars as of 2023, reflecting the company’s value in the eyes of investors. Additionally, it has a negative return on equity of -55.98%, indicating that the company is not generating sufficient returns relative to its shareholders’ investments. Despite this, Lumos Pharma Inc continues to progress towards its goal of treating rare diseases through its innovative therapies.
TRACON Pharmaceuticals is receiving positive feedback from investors following the announcement of their license of product development platform for $3M upfront payment. On the day this news was released, the stock price of TRACON Pharmaceuticals saw an increase, suggesting that the financial markets believe that this license agreement is beneficial for the company. The agreement may provide TRACON with a competitive advantage in the pharmaceuticals industry by allowing them to quickly develop and bring new products to market.
Additionally, the upfront payment could provide a financial boost to TRACON, potentially allowing them to invest more in research and development or other initiatives. Overall, investors seem optimistic about TRACON’s future as this license agreement may signify a positive shift in outlook for the company.